A Single Center Retrospective Study Assessing Safety And Efficacy Of Directly Acting Antiviral Agents For The Treatment Of Hepatitis-C In Kidney Transplant Recipients.
Phase of Trial: Phase IV
Latest Information Update: 28 Dec 2016
At a glance
- Drugs Daclatasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 28 Dec 2016 New trial record
- 22 Dec 2016 Primary endpoint (Sustained virologic response (SVR) at 12 weeks) has been met, according to results published in the Transplantation journal.
- 22 Dec 2016 Results published in the Transplantation journal.